Perspective Therapeutics Newsroom

Perspective Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesNov 25 10:56 ET

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6

Moomoo NewsNov 25 10:33 ET

B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6

BenzingaNov 25 08:06 ET

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16

Moomoo NewsNov 25 07:31 ET

RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk

MT NewswiresNov 25 07:08 ET

Cautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety Concerns

TipRanksNov 25 06:08 ET

Perspective Therapeutics Price Target Cut to $16.00/Share From $22.00 by Oppenheimer

Dow JonesNov 22 09:32 ET

Perspective Therapeutics Is Maintained at Outperform by Oppenheimer

Dow JonesNov 22 09:32 ET

Perspective Therapeutics Analyst Ratings

BenzingaNov 22 09:22 ET

Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16

Moomoo NewsNov 22 08:31 ET

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsNov 22 07:32 ET

Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)

TipRanksNov 22 07:24 ET

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsNov 21 18:32 ET

Cautious Optimism: Justin Walsh's Buy Rating on Perspective Therapeutics Amidst Mixed Trial Results

TipRanksNov 21 18:09 ET

LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsNov 21 12:32 ET

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsNov 19 07:31 ET

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsNov 14 07:33 ET

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsNov 13 11:32 ET

Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsNov 13 08:36 ET

LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsNov 12 22:31 ET